Anemia in PregnancyNCT01193192
A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy
An observational study of Anemia in Pregnancy and Pre-eclampsia, run by Pamlab, L.L.C. at 3 sites in United States.
Trial summary
This study is a multi-site, retrospective chart review to determine the effect of Neevo® or NeevoDHA® (with higher folate and B12) versus standard prenatal vitamins on hemoglobin (Hgb) levels in pregnant women throughout the course of pregnancy. Read more about this study
- Who is it for?
- Ages 21 to 39 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Anemia in Pregnancy, Pre-eclampsia
- What is being tested?
- Neevo® and Prenatal vitamins
- How many people
- 30 participants
- Where
- 3 sitesUnited States
- Study dates
- Jul 2010to Nov 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 39 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Pregnant Women Who Received Neevo®/NeevoDHA® or Another Standard Prenatal Vitamin
Who may be able to join
- Pregnant females, age 21-39, who received either Neevo®/NeevoDHA® or another standard prenatal vitamin (Prenatal vitamins must contain ≤1 mg folic acid, 27-35mg iron, and ≤12mcg vitamin B12).
- Clinical diagnosis of pregnancy must have been made at ≤12 weeks of Pregnancy, and delivery must have occurred on or after January 1, 2008 and on or before March 31, 2010
- Subjects must have been compliant in taking Neevo®/NeevoDHA® or other prenatal vitamin
Who cannot join
- Subjects should not have taken Prenate®, Prenate®DHA, or Prenate® Elite, which are L-methylfolate-containing prenatal vitamins.
- The following supplements within 2 months of diagnosis of pregnancy: B12 injection; > 35mg Iron; > 1.2 mg of folate; or a L-methylfolate product that is not a prenatal vitamin such as Life Extension methylfolate, Prothera methylfolate, Thorne 5-MTHF, Metanx®, Deplin®, Cerefolin®, or CerefolinNAC®
- History of leukemia or any anemia other than iron deficiency anemia or;
- Taking any iron supplement (in addition to the prenatal vitamin) prior to Week 22
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Five Oaks Medical Group
Chickasha, Oklahoma, 73018
Norman Regional Health System
Norman, Oklahoma, 73071
Norman Regional Health System
Norman, Oklahoma, 73072
About this study
This study is a multi-site, retrospective chart review to determine the effect of Neevo® or NeevoDHA® (with higher folate and B12) versus standard prenatal vitamins on hemoglobin (Hgb) levels in pregnant women throughout the course of pregnancy. Neevo® is a prescription medical food indicated for the dietary management of women under a doctor's care who face high risk pregnancies, older overactive bladder (OB) patients and patients unable to fully metabolize folic acid. Data will be collected from existing patient charts of subjects administered Neevo® or NeevoDHA® daily compared to subjects administered a prenatal vitamin daily.
- Conditions
- Anemia in Pregnancy, Pre-eclampsia
- Being tested
- Neevo®, Prenatal vitamins
- Keywords
- Neevo, Neevo DHA, L-methylfolate, anemia during pregnancy, folic acid, vitamin B12, prenatal vitamins, hemoglobin, iron deficiency, Pregnancy
- Medical subject headings
- Pre-Eclampsia, Iron Deficiencies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neevo®Other
A prenatal "medical food" - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid
Prenatal vitaminsOther
for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
| Study group | Role | What they receive |
|---|---|---|
| Arm #1 (Test Group) | 100 subject administered Neevo® or NeevoDHA® daily Receives: Other: Neevo® | |
| Arm #2 (Control group) | 100 subject administered a prenatal vitamin daily Receives: Other: Prenatal vitamins |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Hemoglobin (Hgb) Levels
To determine the effect of Neevo®/NeevoDHA® versus standard prenatal vitamins on mean hemoglobin (Hgb) levels in pregnant women throughout the course of pregnancy.
Measured: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.
Secondary outcomes (4)
Mean Change in Hemoglobin (Hgb) Levels
To determine the effect of Neevo®/NeevoDHA® versus standard prenatal vitamins on mean change in hemoglobin levels in pregnant women.
Measured: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.
Incidence of Anemia
To determine if Neevo®/NeevoDHA® administration during pregnancy results in fewer incidences of anemia than with standard prenatal vitamins.
Measured: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.
Incidence of Pre-eclampsia
To determine if Neevo®/NeevoDHA® administration during pregnancy results in fewer cases of pre-eclampsia than with standard prenatal vitamins.
Measured: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.
Mean Infant Birth Rate
To determine the effect of Neevo®/NeevoDHA® versus standard prenatal vitamins on infant birth weight.
Measured: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2010 (estimated)
- Study startJul 2010
- Primary completionNov 2010
- Study completionNov 2010
Why it stopped: Inadequate number of charts available for Test Group
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Anemia in PregnancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pamlab, L.L.C.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Baylor Health Care System, Norman Regional Health System, Five Oaks Medical Group
- Responsible party
- Sponsor
- Investigators
- Nicole Jarvis, M.D., Principal investigator, Norman Regional Health System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01193192
- Sponsor's protocol ID
- N-002
- Status last verified
- Nov 2011
- First submitted
- 30 Aug 2010
- Last updated
- 23 Nov 2011
- Results posted
- No
- Data monitoring committee
- No
Publications
Bentley S, Hermes A, Phillips D, Daoud YA, Hanna S. Comparative effectiveness of a prenatal medical food to prenatal vitamins on hemoglobin levels and adverse outcomes: a retrospective analysis. Clin Ther. 2011 Feb;33(2):204-10. doi: 10.1016/j.clinthera.2011.02.010. Epub 2011 Mar 25.
PubMed 21440300
Study at a glance
From the registry record, last updated by the sponsor on 23 Nov 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy
- ClinicalTrials.gov ID
- NCT01193192
- Acronym / sponsor ID
- N-002
- Conditions
- Anemia in Pregnancy, Pre-eclampsia
- Keywords
- Neevo, Neevo DHA, L-methylfolate, anemia during pregnancy, folic acid, vitamin B12, prenatal vitamins, hemoglobin
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Inadequate number of charts available for Test Group
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Pamlab, L.L.C.Industry (pharma, biotech, devices)
- Collaborators
- Baylor Health Care System, Norman Regional Health System, Five Oaks Medical Group
- Study start
- Jul 2010
- Primary completion
- Nov 2010 (actual)
- Study completion
- Nov 2010 (actual)
- First posted
- 1 Sep 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a multi-site, retrospective chart review to determine the effect of Neevo® or NeevoDHA® (with higher folate and B12) versus standard prenatal vitamins on hemoglobin (Hgb) levels in pregnant women throughout the course of pregnancy. Neevo® is a prescription medical food indicated for the dietary management of women under a doctor's care who face high risk pregnancies, older overactive bladder (OB) patients and patients unable to fully metabolize folic acid. Data will be collected from existing patient charts of subjects administered Neevo® or NeevoDHA® daily compared to subjects administered a prenatal vitamin daily.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm #1 (Test Group) | – | Other: Neevo®100 subject administered Neevo® or NeevoDHA® daily |
| Arm #2 (Control group) | – | Other: Prenatal vitamins100 subject administered a prenatal vitamin daily |
Who may qualify
- Ages
- 21 to 39 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Pregnant Women Who Received Neevo®/NeevoDHA® or Another Standard Prenatal Vitamin
Key inclusion criteria (3 listed)
- Pregnant females, age 21-39, who received either Neevo®/NeevoDHA® or another standard prenatal vitamin (Prenatal vitamins must contain ≤1 mg folic acid, 27-35mg iron, and ≤12mcg vitamin B12).
- Clinical diagnosis of pregnancy must have been made at ≤12 weeks of Pregnancy, and delivery must have occurred on or after January 1, 2008 and on or before March 31, 2010
- Subjects must have been compliant in taking Neevo®/NeevoDHA® or other prenatal vitamin
Key exclusion criteria (4 listed)
- Subjects should not have taken Prenate®, Prenate®DHA, or Prenate® Elite, which are L-methylfolate-containing prenatal vitamins.
- The following supplements within 2 months of diagnosis of pregnancy: B12 injection; > 35mg Iron; > 1.2 mg of folate; or a L-methylfolate product that is not a prenatal vitamin such as Life Extension methylfolate, Prothera methylfolate, Thorne 5-MTHF, Metanx®, Deplin®, Cerefolin®, or CerefolinNAC®
- History of leukemia or any anemia other than iron deficiency anemia or;
- Taking any iron supplement (in addition to the prenatal vitamin) prior to Week 22
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neevo®A prenatal "medical food" - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid | Other | Arm #1 (Test Group) |
| Prenatal vitaminsfor inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12. | Other | Arm #2 (Control group) |
Primary outcome
Mean Hemoglobin (Hgb) Levels
Time frame: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.
To determine the effect of Neevo®/NeevoDHA® versus standard prenatal vitamins on mean hemoglobin (Hgb) levels in pregnant women throughout the course of pregnancy.
4 secondary outcomes
Mean Change in Hemoglobin (Hgb) Levels
Time frame: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.
Incidence of Anemia
Time frame: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.
Incidence of Pre-eclampsia
Time frame: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.
Mean Infant Birth Rate
Time frame: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.
Results and safety
The study was stopped early (reason given: Inadequate number of charts available for Test Group). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Nov 2011.
- Derived from this study: PubMed 21440300Bentley S, Hermes A, Phillips D, Daoud YA, Hanna S. Comparative effectiveness of a prenatal medical food to prenatal vitamins on hemoglobin levels and adverse outcomes: a retrospective analysis. Clin Ther. 2011 Feb;33(2):204-10. doi: 10.1016/j.clinthera.2011.02.010. Epub 2011 Mar 25.
Related trials for Anemia in Pregnancy
RecruitingPhase 2
Probiotic Supplementation in Optimizing Iron and Hematological Status Among Pregnant Females
Iron Deficiency (ID), Pregnancy
Active, not recruitingPhase 2
Management of Iron Deficiency Anemia in Hemodialysis Patients
Iron Deficiency Anemia (IDA), ESRD (End Stage Renal Disease)
Active, not recruitingPhase 3
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome
Not yet recruitingPhase 1
Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
Chronic Kidney Disease, Anemia
Active, not recruitingObservational study
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
Atypical Hemolytic Uremic Syndrome(aHUS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicole Jarvis, M.D. principal investigator
Norman Regional Health System
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Anemia in Pregnancy and Pre-eclampsia, run by Pamlab, L.L.C. at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 23 Nov 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Inadequate number of charts available for Test Group). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Hemoglobin (Hgb) Levels (time frame: At the time of diagnosis of pregnancy, at the end of the second trimester (Weeks 22-28), and at delivery.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01193192, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Nov 2011.